Drugmaker Pfizer has nearly completed negotiations to take over Medivation, maker of a widely prescribed drug for prostate cancer, in a $14 billion cash deal, people familiar with the matter said. The drug, Xtandi, is already bringing Medivation about $2 billion in sales a year, and analysts say the figure could double or more.
Bloomberg (21 Aug.)
